Evidence map›Paper›PMID 38453621›Full record

ArticleVaccine2024

Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged ≥ 12 years, United States, August 2021-October 2022.

Lu Meng, LaTreace Harris, Lauren Shaw, Hoody Lymon, Hannah Reses, Jeneita Bell, Peng-Jun Lu, Lynn Gibbs-Scharf, Terence Chorba

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lu MengCDC COVID-19 Response Team, USA; Division of Health Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA. Electronic address: PRJ8@cdc.gov.
LaTreace HarrisCDC COVID-19 Response Team, USA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Lauren ShawCDC COVID-19 Response Team, USA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Hoody LymonDivision of Health Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Hannah ResesDivision of Health Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Jeneita BellDivision of Health Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Peng-Jun LuImmunization Services Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Lynn Gibbs-ScharfCDC COVID-19 Response Team, USA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Terence ChorbaCDC COVID-19 Response Team, USA; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Rd NE, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA. Electronic address: TLC2@cdc.gov.
Centers for Disease Control and Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

COVID-19 booster dose vaccination has been crucial in ensuring protection against COVID-19 including recently predominant Omicron variants. Because vaccines against newer SARS-CoV- 2 variants are likely to be recommended in future, it will be valuable to understand past booster dose uptake among different demographic groups. Using U.S. vaccination data, this study examined intervals between primary series completion and receipt of first booster dose (monovalent or bivalent) during August 2021 - October 2022 among persons ≥12 years of age who had completed a COVID-19 vaccine primary series by October 2021. Sub-populations who were late booster recipients (received a booster dose ≥12 months after the primary series) or received no booster dose included persons <35 years old, Johnson & Johnson/Janssen vaccine primary dose recipients, persons in certain racial and ethnic groups, and persons living in rural and more socially vulnerable areas, and in the South region of the United States; these groups may benefit the most from public health outreach efforts to achieve timely COVID-19 vaccination completion in future.

Indexed as

COVID-19COVID-19 VaccinesAdultChildEthnicityHumansSARS-CoV-2United StatesCOVID-19 VaccinesBooster doseCoronavirusCOVID-19COVID-19 vaccination

Identifiers

PMID38453621
PMCPMC11187615
OpenAlexW4392575448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.